Skip to main content

Advertisement

Table 1 Patient and tumor characteristics

From: IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer

  FBLAD-U95 set FBLAD-Exon set
Patients n = 75 n = 125
 Sex
  Male, n (%) 61 (81.3) 100 (80.0)
  Female, n (%) 14 (18.7) 25 (20.0)
 Mean age at surgery, years ± SD 62.8 ± 13.8 69.7 ± 15.2
 Mean follow-up, months ± SD 40.1 ± 40.0 33.6 ± 29.7
Bladder tumors
 Clinical presentation
  Incident tumors, n (%) 58 (77.3) 107 (85.6)
  Recurrent tumors, n (%) 17 (22.7) 18 (14.4)
 TNM 2009 Stage
  Ta, n (%) 24 (32.0) 24 (19.2)
  T1, n (%) 12 (16.0) 32 (25.6)
   T ≥ 2, n (%) 39 (52.0) 69 (55.2)
 WHO 1973 Grade
  G1, n (%) 11 (14.7) 5 (4.0)
  G2, n (%) 23 (30.7) 26 (20.8)
  G3, n (%) 41 (54.7) 94 (75.2)